Dose of repatha
Searched over 200M research papers
Summary
2 papers analyzed
These studies suggest evolocumab effectively reduces LDL-C levels by 50-60% and is valuable for treating various forms of hypercholesterolemia, especially in patients who cannot achieve LDL-C goals with statins alone.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Dosage of Repatha (Evolocumab) for Hyperlipidemia
Introduction to Repatha (Evolocumab)
Repatha, known generically as evolocumab, is a monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9). This medication is used to significantly reduce low-density lipoprotein cholesterol (LDL-C) levels in patients with hyperlipidemia, including those with primary hypercholesterolemia, mixed dyslipidemia, and familial hypercholesterolemia .
Recommended Dosage of Repatha
Standard Dosage
Evolocumab is administered subcutaneously and is available in two dosing regimens:
- 140 mg every two weeks: This regimen is suitable for patients who prefer more frequent dosing.
- 420 mg once monthly: This option is ideal for patients who prefer less frequent dosing .
Efficacy in Clinical Trials
In various phase III clinical trials, evolocumab demonstrated significant efficacy in reducing LDL-C levels. When compared to placebo, evolocumab reduced LDL-C levels by 54.8% to 76.3%. Additionally, when compared to ezetimibe, another cholesterol-lowering medication, evolocumab showed a reduction in LDL-C levels by 36.9% to 47.2%. These results were consistent across different patient populations, including those on statin therapy, statin-intolerant patients, and those with heterozygous or homozygous familial hypercholesterolemia .
Long-Term Efficacy and Safety
The long-term efficacy of evolocumab has been maintained in extended studies, and it has been well tolerated by patients. The safety profile of evolocumab is favorable, with good tolerance observed in clinical trials .
Conclusion
Repatha (evolocumab) is a highly effective treatment for reducing LDL-C levels in patients with various forms of hyperlipidemia. The recommended dosages are 140 mg every two weeks or 420 mg once monthly, providing flexibility based on patient preference. Its efficacy and safety have been well-documented in clinical trials, making it a valuable option for patients struggling to manage their cholesterol levels with traditional therapies.
Sources and full results
Most relevant research papers on this topic
